Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Prime Medicine Inc PRME

Healthcare Biotechnology
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering the gene editing therapies to patients. It deploys its Prime Editing platform, a gene editing technology, to develop a new class of differentiated, one-time genetic therapies. It is engaged in developing Prime Editors as a new class of therapeutics with transformative potential to expand the application of... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:PRME)

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire November 12, 2024

Prime Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire November 6, 2024

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

GlobeNewswire October 24, 2024

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

GlobeNewswire October 15, 2024

Prime Medicine Unveils Strategically Focused Pipeline

GlobeNewswire September 30, 2024

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

GlobeNewswire September 30, 2024

Prime Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire August 28, 2024

Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire August 8, 2024

Prime Medicine to Present at Upcoming Investor Conferences

GlobeNewswire May 30, 2024
View More News ››

Opinion & Analysis (NDAQ:PRME)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:PRME)

$PRME Testing Key Levels, $BOLT.CN Long Setup

$PRME is consolidating near 0.31, hovering just above support at 0.30. A breakout above 0.33 could unlock more upside—volume will be key....
PivotStock22 - 1 day ago

Technical Watch on $PRME and $BOLT.CN

$PRME is showing strong technical signals, trading at 0.31 and holding above key support levels. A move above 0.33 could signal a...
MoneySurge10 - 1 day ago

Prime Medicine, Inc. (NASDAQ:PRME): A Promising Gene Editing

http://beyondspx.com/2024/08/01/prime-medicine-inc-nasdaqprme-a-promising-gene-editing-powerhouse-poised-for-breakthrough/
MikeTester - August 2, 2024

(PRME) Long Term Investment Analysis

Just In: $PRME (PRME) Long Term Investment Analysis2024-06-07 12:02:00 ET Stock Traders Daily has produced this trading report using a...
whytestocks - June 7, 2024

Prime Medicine Announces FDA Clearance of Investigational Ne

NEWS: $PRME Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic...
whytestocks - April 29, 2024

Trend Tracker for (PRME)

News; $PRME Trend Tracker for (PRME)2024-02-12 01:14:00 ET Stock Traders Daily has produced this trading report using a proprietary...
whytestocks - February 12, 2024
View more Bullboard ››

Nicola Mining Inc

Nicola Mining Inc

Nicola Mining Inc. is a Canada-based junior mining company. The Company maintains a 100% owned mill and tailings facility ...
View More »